Triptans survey results


In the vibrant community of Migraine Buddy users, a recent poll within the “to know you better” section has shed light on the experiences of those navigating their journey with migraine, particularly focusing on their treatment satisfaction with triptans. A heartfelt thank you to each participant whose valuable insights not only contribute to a deeper understanding but also foster a supportive network where sharing knowledge becomes a beacon of hope.


Triptans, developed in the 1990s as an acute response to migraine attacks, serve as a cornerstone in migraine management. These “abortive” medications aim to halt the migraine in its tracks, offering relief to those in the throes of an attack. It’s fascinating to see how treatment strategies have evolved, now including preventive medications alongside these abortive solutions.


Delving into the demographics, the average duration of migraine affliction among respondents is a staggering 18 years, with a range from 1 to 63 years. This statistic alone highlights the pervasive and persistent nature of migraine. Among triptan users, a significant 65% reach for their medication in at least three out of four migraine episodes, underscoring the reliance on these treatments for managing symptoms.

When asked about the frequency of triptan use per attack, responses varied:

  • 36% use it for (almost) every attack,
  • 29% for more than 75% of attacks,
  • 19% for about 50% of attacks, and
  • 16% for less than 25% of attacks.

For those who reserve triptans for more severe episodes, the decision underscores the strategic use of medication in managing their condition effectively.

Our survey provided a glimpse into the primary triptans used by the community:

What is the triptan you mostly use?
Sumatriptan (Imitrex) 30%
Rizatriptan (Maxalt) 22%
Zolmitriptan (Zomig) 19%
Eletriptan (Relpax) 11%
Naratriptan (Amerge) 10%
Almotriptan (Axert) 4%
Frovatriptan (Frova) 3%
Sumatriptan+Naproxen (Treximet) 2%

This distribution not only reflects personal preferences and experiences but also the diversity in treatment responses among individuals.



Now, let’s dive into the core findings regarding triptan efficacy and side effects. The satisfaction levels concerning pain reduction are impressively high, with 89% of users satisfied. Similarly, 82% were satisfied with the reduction in attack duration, and 77% appreciated the speed of action. The satisfaction slightly dips when considering the treatment’s impact on other migraine symptoms, with 75% satisfied.

However, the effectiveness in mitigating the cognitive impacts of migraine attacks—such as difficulty thinking or concentrating—shows a mixed response, with 54% satisfied, indicating a significant area for further exploration and improvement.

Dissatisfied Neutral Satisfied
Pain intensity 6% 5% 89%
Attack duration 10% 8% 82%
Speed of action 6% 7% 77%
Other symptoms 9% 6% 75%
Cognition 25% 21% 54%


Side effects remain a crucial aspect of the treatment conversation. The most reported side effects include sleepiness, physical weakness, and challenges in thinking or concentrating, among others. The frequencies of these side effects vary, reflecting the complex interplay between efficacy and tolerability in migraine management.

Half the time or more Less than half the time Rarely Never
Nausea 9% 8% 26% 56%
Sleepiness 36% 18% 25% 21%
Dizziness 14% 12% 34% 40%
Physical weakness 22% 16% 31% 31%
Difficulty breathing 2% 5% 14% 79%
Digestion issue/stomach pain 5% 7% 25% 63%
Difficulty in thinking/concentrating 20% 18% 34% 28%
Working memory problems 8% 15% 35% 41%
Productivity impairment 24% 18% 32% 26%
Anxiety 3% 6% 24% 68%


In conclusion, the insights garnered from this community-driven survey within the Migraine Buddy app offer a compelling snapshot of how individuals grappling with migraine perceive and utilize triptans in their treatment regimen. The detailed feedback on efficacy, frequency of use, preferred types of triptans, and encountered side effects enriches our collective understanding of the migraine experience from a patient-centered perspective.

It’s crucial to highlight that this survey was conducted independently, rooted in the authentic voices and experiences of our community members, without any influence or support from the pharmaceutical industry. This independence ensures that the findings reflect the real-world scenarios and challenges faced by those living with migraine, providing a transparent and unbiased look into how triptans fit into their lives.

The varied responses underscore the uniqueness of each individual’s journey with migraine, revealing a broad spectrum of satisfaction levels, treatment preferences, and side effect profiles. While triptans remain a cornerstone of migraine management for many, the quest for more comprehensive and personalized treatment strategies, especially concerning cognitive impacts and side effects, is evident.

This survey not only fosters a deeper sense of community and shared understanding but also serves as a reminder of the critical importance of patient-centered research. By continuing to share, listen, and learn from each other, we pave the way for more informed, empathetic, and effective approaches to managing migraine.

Let us move forward, buoyed by the knowledge shared and the connections strengthened through this survey, as we continue to explore and advocate for solutions that address the full spectrum of migraine experiences. Together, we are a powerful force for change, driving toward a future where every individual with migraine feels understood, supported, and empowered in their treatment journey.

Jenny from Migraine Buddy

You Will Also Like

Back to Blog

Leave your mobile to get a link to download the app